It is generally accepted that during tumor progression an inflammatory response operates locally promoting systemic changes, among which a sustained decline in insulin sensitivity would allow the redistribution of glucose from major consumers (e.g. skeletal muscle) to tumor cells. Here, INS is linked to neoplasm.